Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody (HRP) (3531) was raised against a peptide corresponding to 10 amino acids near the amino terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein. The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.
Konjugation:
HRP
Alternative Synonym:
2019-nCoV) Envelope Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), E protein, Envelope protein, SARS-CoV-2 (COVID-19, covid-19, sars-cov-2
SARS-CoV-2 (COVID-19) Envelope Antibody is supplied in PBS containing 0.02% sodium azide.
Formulierung:
Liquid
Application Verdünnung:
Optimal dilutions for each application to be determined by the researcher.
Anwendungsbeschreibung:
IHC: 2 µg/mL Antibody validated: Immunohistochemistry in COVID-19 patient samples. All other applications and species not yet tested.
Figure 2 ELISA Validation Coating Antigen: immunogen peptide, 3531P, 10 &956,g/mL, incubate at 4 &730,C overnight.Detection Antibodies: SARS-CoV-2 Spike antibody, 3531-HRP or 3531, dilution: 0.5-1000 ng/mL, incubate at RT for 1 hr.3531 was detected by anti-rabbit HRP-conjugated secondary antibodies at 1:10,000, incubate at RT for 1 hr.
Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Envelope Protein in COVID-19 Patient Lung Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) envelope antibody (3531-HRP, 2 &956,g/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT, antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4&730,C. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 envelope protein was observed in macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
